Compare Amgen, Inc. (AMGN) vs WD 40 Company (WDFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs WD 40 Company — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while WD 40 Company trades at $267.3 (market cap $3.56B). The key difference: Amgen, Inc. is far larger — about 55.1× WD 40 Company's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WDFC | |
|---|---|---|
Market Cap | $196.12B | $3.56B |
Sector | Health | Technology |
52-Week High | $388.16 | $264.91 |
52-Week Low | $271.18 | $187.52 |
Enterprise Value | $241.41B | $3.61B |
Dividend Yield | 2.77% | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
WDFC stock trades at $264.91, up 10.65% ($25.49) on strong Q2 2026 earnings that beat estimates with EPS of $2.33 versus $1.58 expected. The technical outlook is bullish with support at $237 and resistance at $245. Fundamentals show robust revenue growth to $675M in 2026 and a net income margin of 13.22%, though valuation multiples like a P/E of 40.28 appear elevated. Positive media coverage highlights the company's strong brand and consistent performance.
The outlook remains positive given earnings beats and brand strength, but high valuation and margin pressure from input costs pose risks. Analyst consensus is mostly neutral with 71% hold ratings, suggesting cautious optimism. The stock offers stability but may face headwinds if growth slows or costs rise further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
